Hyperglycemia is an excess of glucose in the bloodstream, and is often associated with diabetes mellitus. It occurs when the body does not have enough insulin to control the sugar level or unable to produce the insulin. Furthermore, hyperglycemia if remains untreated may cause serious complications such as nerve damage or neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease, and skin problems such as bacterial and fungal infections. The major signs of hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate often), and a dry mouth.
Increasing prevalence of diabetes, and growing investment in biotechnology and pharmaceutical industries, and rising need for the better treatment methods drive the growth of the market.
According to the WHO, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes. Another, 2.2 million deaths were attributed to high blood glucose level in 2012.
According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies across the globe. This is higher than the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
Moreover, increasing awareness about diabetes care and management, and advancing technology in medical devices are adding fuel to the growth of the market. Furthermore, increasing prevalence of obesity and consumption of unhealthy diet also drive the market growth.
However, availability of expensive treatment and poor reimbursement policy are some of the factors, which may slow the market growth during the forecast period.
The global hyperglycemia treatment market is expected to grow at a CAGR of 9.8 % during the forecast period 2017-2023.
Segmentations
The global hyperglycemia treatment market is segmented on the basis of treatment, mode of administration, and end user.
On the basis of treatment, it is segmented into fluid replacement, electrolyte replacement, insulin therapy, and drugs. The drugs segment is further segmented into sulfonylureas, biguanides, thiazolidinediones, and others.
On the basis of mode of administration, it is segmented into topical, oral, and others.
On the basis of end user, the market is segmented into hospitals & clinics, retail pharmacy, and others
Key Players
Some of key the players in the market are Novo Nordisk A/S, Merck & Company Inc., Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd., Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb., and Abbott.
Request Customization
Get a Sample
Get a Sample
Request Customization